为了探讨在门诊使用合成材料宫颈扩张器（Dilapan）对条件不成熟的宫颈促成熟的安全性。作者将42名孕妇分为门诊组和住院组，用DilaPan促宫颈成熟，引产用药指征是孕周＞37周，BISh。p评分在4分或4分以下，经无刺激试验（NST）或生物物理测评（BPP）证明胎儿健康，没有临产也无分娩禁忌症。胎膜早破，绒毛膜羊膜炎小链球菌感染和胎心监护无反应者均除外。插入前消毒宫颈，无菌操作将DilaPan放入宫颈内，使用DilaPan的数目视以宫颈容纳为度。放在宫颈内至少sh，插入DllaPan后，所有病人需监测宫缩lh，若无宫缩，胎心率正常可让门诊促宫颈成熟病人回家，嘱按时回院引产分娩。有规律子宫收缩，阴道出血，胎膜早破或胎动减少者即到产房。住院组所有病人在催产素引产前作BISh0P评分，由同一作者在插入前和去除DihPan后作Bishop评分。结果：42例病人分成2组，门诊组和住院组各州人。2组之间在年龄、孕次，产次或孕周、分娩方式，新生儿体重或APgar评分等项均无显著差异。在促宫颈成熟后的评分，使用DilaPan的总数或从插入到分娩开始的间隔时间无显著差异。2组有关的催产素引产间隔时间（分别为11土7或14土7h）无显著差异。但住院时间分别为sl土27对70土ZOh，P＜O．OO7）有显著差异。尽管住院时间缩短些，但2组 In order to investigate the safety of using a synthetic cervical dilapan at an outpatient setting to immature cervix to promote ripening. The authors divided 42 pregnant women into outpatient groups and inpatient groups, and developed cervical ripening with DilaPan. Indications for induction of labor were gestational weeks> 37 weeks, BISh. p score of 4 points or less, no stimulation test (NST) or biophysical evaluation (BPP) to prove the health of the fetus, there is no labor nor childbirth contraindications. Premature rupture of membranes, chorioamnionitis and fetal heart rate monitoring were non-responders are excluded. Sterilization of cervical before insertion, aseptic DilaPan into the cervix, the number of DilaPan depending on the degree of cervical accommodation. Placed in the cervix at least sh, insert DllaPan, all patients need to monitor uterine contractions lh, if no contractions, fetal heart rate can be normal outpatient cervical mature patients go home, and promptly back to the hospital induced labor childbirth. Regular uterine contractions, vaginal bleeding, premature rupture of membranes or fetal movement that is, to the delivery room. All patients in the hospital group were given BIShOP scores before oxytocin induction and Bishop scores were assessed by the same author before and after DihPan. Results: Forty-two patients were divided into two groups, outpatient group and in-hospital group. There was no significant difference between the two groups in terms of age, gestational age, parity or gestational age, mode of delivery, weight of newborn or APgar score. There was no significant difference in the score after cervical ripening, the total number of DilaPan used, or the interval from insertion to delivery. There were no significant differences between the two groups in terms of induction of oxytocin intervals (11 ± 7 or 14 ± 7 h, respectively). However, hospitalization time was 27 for soil sl to 70 soil ZOh, P